{"protocolSection": {"identificationModule": {"nctId": "NCT02625090", "orgStudyIdInfo": {"id": "EP0073"}, "secondaryIdInfos": [{"id": "2015-001268-20", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "UCB Pharma", "class": "INDUSTRY"}, "briefTitle": "An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy", "officialTitle": "An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of UCB0942 When Used as Adjunctive Therapy for Partial-onset Seizures in Adult Subjects With Highly Drug-resistant Focal Epilepsy"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "TERMINATED", "whyStopped": "Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-12-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-11-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-11-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-12-04", "studyFirstSubmitQcDate": "2015-12-04", "studyFirstPostDateStruct": {"date": "2015-12-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-11-23", "resultsFirstSubmitQcDate": "2021-11-23", "resultsFirstPostDateStruct": {"date": "2022-01-31", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-03-08", "lastUpdatePostDateStruct": {"date": "2022-03-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "UCB Biopharma SRL", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy. Also, the effects of UCB0942 on the patient's quality of life will be explored.", "detailedDescription": "For those subjects who benefit substantially from UCB0942 in the multicenter, randomized, double-blind, placebo-controlled, parallel group study EP0069, the current open-label extension study EP0073 will provide an opportunity to continue UCB0942 treatment after a careful evaluation of the individual benefit-risk balance and with close monitoring of safety, tolerability and efficacy of long-term study treatment."}, "conditionsModule": {"conditions": ["Highly Drug-resistant Focal Epilepsy"], "keywords": ["Drug-resistance", "focal epilepsy", "partial-onset seizures"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 42, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "UCB0942", "type": "EXPERIMENTAL", "description": "UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.\n\nThe Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart.", "interventionNames": ["Drug: UCB0942"]}], "interventions": [{"type": "DRUG", "name": "UCB0942", "description": "* Active Substance: UCB0942\n* Pharmaceutical form: Film-coated tablet\n* Concentration: 25 mg, 100 mg or 200 mg\n* Route of Administration: oral", "armGroupLabels": ["UCB0942"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) From the Beginning at Entry Visit (EV) of the Evaluation Period to End of Safety Follow-Up Visit During the EP0073 Study", "description": "An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.\n\nPercentage of participants experiencing at least one treatment-emergent adverse event (reported by the participant and/or caregiver or observed by the Investigator or inpatient staff) are reported.", "timeFrame": "From Entry Visit to End of Safety Follow-Up Visit (up to 5 years)"}, {"measure": "75% Responder Rate by 3-month Interval (Month 0 to 3) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month 0-3)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >3-6) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >3-6)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >6-9) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >6-9)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >9-12) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >9-12)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >12-15) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >12-15)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >15-18) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >15-18)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >18-21) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >18-21)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >21-24) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >21-24)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >24-27) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >24-27)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >27-30) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >27-30)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >30-33) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >30-33)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >33-36) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >33-36)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >36-39) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >36-39)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >39-42) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >39-42)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >42-45) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >42-45)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >45-48) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >45-48)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >48-51) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >48-51)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >51-54) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >51-54)"}, {"measure": "75% Responder Rate by 3-month Interval (Month >54-57) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >54-57)"}], "secondaryOutcomes": [{"measure": "Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study", "description": "Median partial-onset seizure frequency per 28 days by 3-month intervals over the Evaluation Period of the EP0073 study was reported.", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period"}, {"measure": "Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study", "description": "Median partial-onset seizure frequency per 28 days by seizure type (Type IA1, Type IB, Type IC) by 3-month intervals over the Evaluation Period of the EP0073 study was reported. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981.", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period"}, {"measure": "Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study", "description": "Percent change from Baseline in seizure frequency for observable focal-onset seizures (Type IA1, IB, and IC) to the corresponding interval was calculated using the following formula: change from Baseline in the 28 day adjusted seizure frequency/28 day adjusted seizure frequency during the EP0069 2- week Prospective Outpatient Baseline Period \u00d7 100. The numerator is calculated by subtracting the 28-day adjusted seizure frequency during the Period of interest from the 28-day adjusted seizure frequency during the EP0069 2-week prospective outpatient Baseline Period. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981.", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period, Relative to Baseline (of EP0069)"}, {"measure": "50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study", "description": "A 50% responder was defined as a participant with a \u226550% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 50% responders during the period/number of participants during the period \u00d7 100.", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period"}, {"measure": "Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period", "description": "The number of seizure-free days is defined as the total number of days within an analysis Period or time interval for which no seizures were reported. The percentage of seizure-free days is to be computed as 100 times the number of seizure-free days divided by the number of days for which daily diary data was available in the specified analysis Period. Days without the corresponding daily diary data (ie, \"Not Done\" is ticked) are not used in these computations.", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period"}, {"measure": "Seizure-free Rate Over the Evaluation Period", "description": "Participants were considered seizure free for a given Period or time interval if the participant, completes the Period or time interval, reports no seizures during the Period, and has no more than 10% of days in the Period for which seizure data is not available (ie, \"Not Done\" is reported on the Seizure Count CRF). The seizure freedom rate (%) for a specific time Period was calculated using the following formula: Count of seizure free participants during the Period/ Number of participants during the Period \u00d7 100.", "timeFrame": "Over the Evaluation Period (up to 5 years)"}, {"measure": "Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073", "description": "The QOLIE-31-P includes 30 items grouped into 7 multi-item subscales (seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive functioning, medication effects, and social function) and a health status item. Individual responses for the 30 subscale items are rescaled to 0 to 100 with higher scores reflecting better functioning. Each subscale score is then calculated by summing rescaled responses for that subscale and dividing by number of items with non-missing response. Responses for health status item are multiple of 10 ranging from 0 to 100 with a higher score corresponding to better health status. The QOLIE-31-P total score was calculated as weighted sum of the subscale scores which ranges from 0 to 100 with higher score reflecting better functioning.", "timeFrame": "Month 3, 7, 13, 19, 25, 31, 37, 43, 49, early discontinuation visit (EDV) (up to Month 58), Relative to Baseline (of EP0069)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* A written Informed Consent form approved by the Independent Ethics Committee is signed and dated by the subject, after the Investigator assesses whether the subject is able to understand the potential risks and benefits of participating in the study\n* Subject must have completed Visit 13 (V13) of the Outpatient Maintenance Period of EP0069 to be eligible for enrollment into EP0073\n* In EP0069, the subject demonstrated a reduction in frequency and/or severity of seizures as compared to baseline that is considered clinically significant by the Investigator and significant by the subject\n* In EP0069, the subject experiences substantial benefit from UCB0942 with acceptable tolerability according to the subject and Investigator\n* No tolerability issues that can outweigh attained benefits, in the opinion of the Investigator\n* Female subjects of nonchildbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, and complete hysterectomy) are eligible. Female subjects of childbearing potential are eligible if they use medically accepted contraceptive methods\n* Male subject confirms that, during the study period and for a period of 3 months after the final dose, when having sexual intercourse with a woman of childbearing potential, he will use a barrier contraceptive (eg, condom)Exclusion Criteria:\n* Subject has active suicidal ideation as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the 'Since Last Visit' version of the Columbia Suicide Severity Rating Scale. The subject should be referred immediately to a Mental Healthcare Professional and must be withdrawn from the study\n* Subject has taken other (non-Anti-Epileptic Drug) prescription, non-prescription, dietary (eg, grapefruit or passion fruit), or herbal products that are potent inducers or inhibitors of the CYP3A4 pathway for 2 weeks (or 5 half lives whichever is longer) prior to study entry\n* Subject has an abnormality in the 12-lead electrocardiography that, in the opinion of the Investigator, increases the risks associated with participating in the study. In addition, any subject with any of the following findings will be excluded:\n\n  1. Prolonged QTc (Bazett's, machine-read) interval defined as \\> 450 ms for males and \\> 470 ms for females\n  2. Bundle branch blocks and other conduction abnormalities other than mild first degree atrioventricular block (defined as PR interval \\>= 220 ms)\n  3. Irregular rhythms other than sinus arrhythmia or occasional, rare supraventricular or rare ventricular ectopic beats\n  4. In the judgment of the Investigator, T-wave configurations are not of sufficient quality for assessing QT interval duration\n* Subject has a clinically significant abnormality on echocardiography at the Entry Visit (V2) of EP0073\n* Upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \\>ULN total bilirubin (\\>=1.5xULN total bilirubin if known Gilbert's syndrome) at the EV (V2) of EP0073 (V15 of EP0069). If subject has elevations only in total bilirubin that are \\>ULN and \\<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \\<35%). For enrolled subjects with a baseline result\n\n  * ULN for ALT, AST, ALP, or total bilirubin, a baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the electronic Case Report form (eCRF). If subject has \\>ULN ALT, AST, or ALP that does not meet the exclusion limit at screening (ie, the value is\n  * ULN but \\<=2xULN at the EV \\[V2\\] of EP0073), repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject must be discussed with the Medical Monitor", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "UCB Cares", "affiliation": "+1 844 599 2273 (UCB)", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Ep0073 103", "city": "Brussels", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Ep0073 101", "city": "Ghent", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Ep0073 102", "city": "Leuven", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Ep0073 201", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Ep0073 402", "city": "Bielefeld", "country": "Germany", "geoPoint": {"lat": 52.03333, "lon": 8.53333}}, {"facility": "Ep0073 403", "city": "Radeberg", "country": "Germany", "geoPoint": {"lat": 51.11112, "lon": 13.91199}}, {"facility": "Ep0073 405", "city": "Ravensburg", "country": "Germany", "geoPoint": {"lat": 47.78198, "lon": 9.61062}}, {"facility": "Ep0073 601", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Ep0073 602", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Ep0073 302", "city": "Heeze", "country": "Netherlands", "geoPoint": {"lat": 51.3828, "lon": 5.57145}}, {"facility": "Ep0073 502", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Ep0073 505", "city": "L'Hospitalet de Llobregat", "country": "Spain", "geoPoint": {"lat": 41.35967, "lon": 2.10028}}, {"facility": "Ep0073 506", "city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Ep0073 501", "city": "Sevilla", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Ep0073 503", "city": "Valencia", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participant flow refers to the Safety Set. Participants who experienced substantial benefit from UCB0942 with acceptable tolerability in the EP0069 (NCT02495844) study had opportunity to continue treatment in this study.", "recruitmentDetails": "The study started to enroll study participants in December 2015 and concluded in November 2020.", "groups": [{"id": "FG000", "title": "UCB0942", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 milligrams (mg) (50 mg twice daily \\[bid\\]), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}]}], "dropWithdraws": [{"type": "Participant wants to be pregnant", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "For the Promoter", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Sponsor's Decision", "reasons": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "Somnolence", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Study terminated by Sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "Negative Benefit/Risk", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "16"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Baseline Characteristics refer to the Safety Set (SS) consisted of all enrolled study participants who took at least 1 dose of UCB0942 in the EP0073 study.", "groups": [{"id": "BG000", "title": "UCB0942", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg twice daily \\[bid\\]), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "42"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "42"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.4", "spread": "10.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}]}]}, {"title": "Other/mixed", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) From the Beginning at Entry Visit (EV) of the Evaluation Period to End of Safety Follow-Up Visit During the EP0073 Study", "description": "An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.\n\nPercentage of participants experiencing at least one treatment-emergent adverse event (reported by the participant and/or caregiver or observed by the Investigator or inpatient staff) are reported.", "populationDescription": "The Safety Set (SS) consisted of all enrolled study participants who took at least 1 dose of UCB0942 in the EP0073 study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From Entry Visit to End of Safety Follow-Up Visit (up to 5 years)", "groups": [{"id": "OG000", "title": "UCB0942 (SS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the Safety Set (SS)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "90.5"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month 0 to 3) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The Full Analysis Set (FAS) consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month 0-3)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24.4"}]}]}]}, {"type": "SECONDARY", "title": "Median Partial-onset Seizure Frequency Per 28 Days by 3-month Intervals Over the Evaluation Period of the EP0073 Study", "description": "Median partial-onset seizure frequency per 28 days by 3-month intervals over the Evaluation Period of the EP0073 study was reported.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number analyzed signifies participants who were evaluable at specified time points.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "seizure frequency per 28 days", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "classes": [{"title": "Month 0-3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.98", "lowerLimit": "10.89", "upperLimit": "48.22"}]}]}, {"title": "Month >3-6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.99", "lowerLimit": "13.07", "upperLimit": "66.18"}]}]}, {"title": "Month >6-9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "23.33", "lowerLimit": "8.09", "upperLimit": "56.00"}]}]}, {"title": "Month >9-12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.67", "lowerLimit": "6.84", "upperLimit": "37.96"}]}]}, {"title": "Month >12-15", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "23.23", "lowerLimit": "9.02", "upperLimit": "49.47"}]}]}, {"title": "Month >15-18", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.91", "lowerLimit": "11.20", "upperLimit": "41.48"}]}]}, {"title": "Month >18-21", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.80", "lowerLimit": "8.09", "upperLimit": "42.00"}]}]}, {"title": "Month >21-24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.31", "lowerLimit": "5.91", "upperLimit": "36.09"}]}]}, {"title": "Month >24-27", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.31", "lowerLimit": "8.71", "upperLimit": "38.53"}]}]}, {"title": "Month >27-30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.16", "lowerLimit": "5.91", "upperLimit": "38.58"}]}]}, {"title": "Month >30-33", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.80", "lowerLimit": "7.78", "upperLimit": "42.62"}]}]}, {"title": "Month >33-36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.29", "lowerLimit": "6.84", "upperLimit": "46.67"}]}]}, {"title": "Month >36-39", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.69", "lowerLimit": "7.16", "upperLimit": "45.11"}]}]}, {"title": "Month >39-42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.96", "lowerLimit": "5.91", "upperLimit": "57.24"}]}]}, {"title": "Month >42-45", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.07", "lowerLimit": "3.73", "upperLimit": "63.17"}]}]}, {"title": "Month >45-48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.58", "lowerLimit": "2.80", "upperLimit": "59.42"}]}]}, {"title": "Month >48-51", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.02", "lowerLimit": "1.56", "upperLimit": "48.16"}]}]}, {"title": "Month >51-54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.80", "lowerLimit": "3.73", "upperLimit": "33.60"}]}]}, {"title": "Month >54-57", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.84", "lowerLimit": "7.84", "upperLimit": "7.84"}]}]}]}, {"type": "SECONDARY", "title": "Median Partial-onset Seizure Frequency Per 28 Days by Seizure Type by 3-month Intervals Over the Evaluation Period of the EP0073 Study", "description": "Median partial-onset seizure frequency per 28 days by seizure type (Type IA1, Type IB, Type IC) by 3-month intervals over the Evaluation Period of the EP0073 study was reported. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number analyzed signifies participants who were evaluable at specified time points.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "seizure frequency per 28 days", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "classes": [{"title": "Type IA1: Month 0-3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "2.18"}]}]}, {"title": "Type IA1: Month >3-6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "7.47"}]}]}, {"title": "Type IA1: Month >6-9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "4.36"}]}]}, {"title": "Type IA1: Month >9-12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IA1: Month >12-15", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "1.24"}]}]}, {"title": "Type IA1: Month >15-18", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "1.87"}]}]}, {"title": "Type IA1: Month >18-21", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "4.36"}]}]}, {"title": "Type IA1: Month >21-24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "2.80"}]}]}, {"title": "Type IA1: Month >24-27", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "3.27"}]}]}, {"title": "Type IA1: Month >27-30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.93"}]}]}, {"title": "Type IA1: Month >30-33", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "2.49"}]}]}, {"title": "Type IA1: Month >33-36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "2.49"}]}]}, {"title": "Type IA1: Month >36-39", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "3.42"}]}]}, {"title": "Type IA1: Month >39-42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "2.80"}]}]}, {"title": "Type IA1: Month >42-45", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "7.47"}]}]}, {"title": "Type IA1: Month >45-48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "4.67"}]}]}, {"title": "Type IA1: Month >48-51", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "3.73"}]}]}, {"title": "Type IA1: Month >51-54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "1.87"}]}]}, {"title": "Type IA1: Month >54-57", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.48", "lowerLimit": "4.48", "upperLimit": "4.48"}]}]}, {"title": "Type IB: Month 0-3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.73", "lowerLimit": "4.67", "upperLimit": "35.00"}]}]}, {"title": "Type IB: Month >3-6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.67", "lowerLimit": "1.56", "upperLimit": "28.00"}]}]}, {"title": "Type IB: Month >6-9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.33", "lowerLimit": "0.00", "upperLimit": "34.68"}]}]}, {"title": "Type IB: Month >9-12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.64", "lowerLimit": "1.24", "upperLimit": "26.11"}]}]}, {"title": "Type IB: Month >12-15", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.56", "lowerLimit": "0.93", "upperLimit": "34.84"}]}]}, {"title": "Type IB: Month >15-18", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.38", "lowerLimit": "2.18", "upperLimit": "37.64"}]}]}, {"title": "Type IB: Month >18-21", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.07", "lowerLimit": "0.62", "upperLimit": "33.91"}]}]}, {"title": "Type IB: Month >21-24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.78", "lowerLimit": "0.93", "upperLimit": "25.20"}]}]}, {"title": "Type IB: Month >24-27", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.80", "lowerLimit": "2.49", "upperLimit": "27.38"}]}]}, {"title": "Type IB: Month >27-30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.49", "lowerLimit": "1.87", "upperLimit": "33.75"}]}]}, {"title": "Type IB: Month >30-33", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.64", "lowerLimit": "3.11", "upperLimit": "32.98"}]}]}, {"title": "Type IB: Month >33-36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.47", "lowerLimit": "2.49", "upperLimit": "25.67"}]}]}, {"title": "Type IB: Month >36-39", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.53", "lowerLimit": "3.73", "upperLimit": "35.47"}]}]}, {"title": "Type IB: Month >39-42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.84", "lowerLimit": "0.31", "upperLimit": "24.58"}]}]}, {"title": "Type IB: Month >42-45", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.29", "lowerLimit": "2.18", "upperLimit": "20.84"}]}]}, {"title": "Type IB: Month >45-48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.36", "lowerLimit": "1.24", "upperLimit": "26.96"}]}]}, {"title": "Type IB: Month >48-51", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.67", "lowerLimit": "0.31", "upperLimit": "43.87"}]}]}, {"title": "Type IB: Month >51-54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.29", "lowerLimit": "1.06", "upperLimit": "33.60"}]}]}, {"title": "Type IB: Month >54-57", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.36", "lowerLimit": "3.36", "upperLimit": "3.36"}]}]}, {"title": "Type IC: Month 0-3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >3-6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >6-9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >9-12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >12-15", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >15-18", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >18-21", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >21-24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >24-27", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >27-30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >30-33", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >33-36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >36-39", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.31"}]}]}, {"title": "Type IC: Month >39-42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >42-45", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}, {"title": "Type IC: Month >45-48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.31"}]}]}, {"title": "Type IC: Month >48-51", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.31"}]}]}, {"title": "Type IC: Month >51-54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "1.87"}]}]}, {"title": "Type IC: Month >54-57", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change in Partial-onset Seizure Frequency Relative to the Baseline Period Defined in EP0069 by 3-month Intervals Over the Evaluation Period of the EP0073 Study", "description": "Percent change from Baseline in seizure frequency for observable focal-onset seizures (Type IA1, IB, and IC) to the corresponding interval was calculated using the following formula: change from Baseline in the 28 day adjusted seizure frequency/28 day adjusted seizure frequency during the EP0069 2- week Prospective Outpatient Baseline Period \u00d7 100. The numerator is calculated by subtracting the 28-day adjusted seizure frequency during the Period of interest from the 28-day adjusted seizure frequency during the EP0069 2-week prospective outpatient Baseline Period. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment and number analyzed signifies participants who were evaluable at specified time points.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percent change", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period, Relative to Baseline (of EP0069)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "classes": [{"title": "Month 0-3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "50.51", "lowerLimit": "21.74", "upperLimit": "72.53"}]}]}, {"title": "Month >3-6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "39.14", "lowerLimit": "12.50", "upperLimit": "72.78"}]}]}, {"title": "Month >6-9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "56.98", "lowerLimit": "31.19", "upperLimit": "72.22"}]}]}, {"title": "Month >9-12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "62.22", "lowerLimit": "39.99", "upperLimit": "80.54"}]}]}, {"title": "Month >12-15", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "55.74", "lowerLimit": "40.95", "upperLimit": "72.78"}]}]}, {"title": "Month >15-18", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "54.04", "lowerLimit": "35.71", "upperLimit": "72.72"}]}]}, {"title": "Month >18-21", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "57.27", "lowerLimit": "39.42", "upperLimit": "76.28"}]}]}, {"title": "Month >21-24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "68.57", "lowerLimit": "46.67", "upperLimit": "76.67"}]}]}, {"title": "Month >24-27", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "60.15", "lowerLimit": "40.31", "upperLimit": "77.41"}]}]}, {"title": "Month >27-30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "59.82", "lowerLimit": "44.79", "upperLimit": "80.06"}]}]}, {"title": "Month >30-33", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "59.57", "lowerLimit": "41.94", "upperLimit": "76.17"}]}]}, {"title": "Month >33-36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "59.73", "lowerLimit": "35.42", "upperLimit": "78.96"}]}]}, {"title": "Month >36-39", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "64.50", "lowerLimit": "45.56", "upperLimit": "78.90"}]}]}, {"title": "Month >39-42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "59.01", "lowerLimit": "37.78", "upperLimit": "80.06"}]}]}, {"title": "Month >42-45", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "68.79", "lowerLimit": "38.39", "upperLimit": "80.00"}]}]}, {"title": "Month >45-48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "68.17", "lowerLimit": "56.98", "upperLimit": "85.00"}]}]}, {"title": "Month >48-51", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "67.12", "lowerLimit": "51.67", "upperLimit": "91.67"}]}]}, {"title": "Month >51-54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "73.08", "lowerLimit": "61.92", "upperLimit": "80.00"}]}]}, {"title": "Month >54-57", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "73.56", "lowerLimit": "73.56", "upperLimit": "73.56"}]}]}]}, {"type": "SECONDARY", "title": "50% Responder Rate by 3-month Intervals Over the Evaluation Period of the EP0073 Study", "description": "A 50% responder was defined as a participant with a \u226550% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 50% responders during the period/number of participants during the period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment and number analyzed signifies participants who were evaluable at specified time points.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "classes": [{"title": "Month 0-3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "51.2"}]}]}, {"title": "Month >3-6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "39.0"}]}]}, {"title": "Month >6-9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "58.8"}]}]}, {"title": "Month >9-12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "67.9"}]}]}, {"title": "Month >12-15", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "65.4"}]}]}, {"title": "Month >15-18", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "53.8"}]}]}, {"title": "Month >18-21", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "57.7"}]}]}, {"title": "Month >21-24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "72.7"}]}]}, {"title": "Month >24-27", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "69.6"}]}]}, {"title": "Month >27-30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "66.7"}]}]}, {"title": "Month >30-33", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "70.0"}]}]}, {"title": "Month >33-36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "65.0"}]}]}, {"title": "Month >36-39", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "72.2"}]}]}, {"title": "Month >39-42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "72.2"}]}]}, {"title": "Month >42-45", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "64.3"}]}]}, {"title": "Month >45-48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "80.0"}]}]}, {"title": "Month >48-51", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "90.0"}]}]}, {"title": "Month >51-54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "80.0"}]}]}, {"title": "Month >54-57", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Seizure-free Days by 3-month Intervals Over the Evaluation Period", "description": "The number of seizure-free days is defined as the total number of days within an analysis Period or time interval for which no seizures were reported. The percentage of seizure-free days is to be computed as 100 times the number of seizure-free days divided by the number of days for which daily diary data was available in the specified analysis Period. Days without the corresponding daily diary data (ie, \"Not Done\" is ticked) are not used in these computations.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number analyzed signifies participants who were evaluable at specified time points.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage of days", "timeFrame": "Over the 3-month interval: Month 0-3, >3-6, >6-9, >9-12, >12-15, >15-18, >18-21, >21-24, >24-27, >27-30, >30-33, >33-36, >36-39, >39-42, >42-45, >45-48, >48-51, >51-54, >54-57 over the Evaluation Period", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "classes": [{"title": "Month 0-3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "48.33", "lowerLimit": "24.44", "upperLimit": "76.67"}]}]}, {"title": "Month >3-6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "42.81", "lowerLimit": "8.89", "upperLimit": "68.89"}]}]}, {"title": "Month >6-9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "54.44", "lowerLimit": "10.00", "upperLimit": "80.00"}]}]}, {"title": "Month >9-12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "55.56", "lowerLimit": "25.56", "upperLimit": "78.89"}]}]}, {"title": "Month >12-15", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "54.44", "lowerLimit": "22.22", "upperLimit": "78.89"}]}]}, {"title": "Month >15-18", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "51.11", "lowerLimit": "25.56", "upperLimit": "73.33"}]}]}, {"title": "Month >18-21", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "61.11", "lowerLimit": "26.67", "upperLimit": "80.00"}]}]}, {"title": "Month >21-24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "57.78", "lowerLimit": "30.00", "upperLimit": "86.67"}]}]}, {"title": "Month >24-27", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "60.00", "lowerLimit": "31.11", "upperLimit": "77.22"}]}]}, {"title": "Month >27-30", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "64.44", "lowerLimit": "22.22", "upperLimit": "85.56"}]}]}, {"title": "Month >30-33", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "57.78", "lowerLimit": "28.89", "upperLimit": "80.00"}]}]}, {"title": "Month >33-36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "60.00", "lowerLimit": "21.11", "upperLimit": "77.78"}]}]}, {"title": "Month >36-39", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "68.89", "lowerLimit": "24.44", "upperLimit": "77.78"}]}]}, {"title": "Month >39-42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "67.78", "lowerLimit": "16.67", "upperLimit": "88.89"}]}]}, {"title": "Month >42-45", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "67.78", "lowerLimit": "6.67", "upperLimit": "86.67"}]}]}, {"title": "Month >45-48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "72.22", "lowerLimit": "11.11", "upperLimit": "91.11"}]}]}, {"title": "Month >48-51", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "73.33", "lowerLimit": "4.00", "upperLimit": "94.44"}]}]}, {"title": "Month >51-54", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "80.65", "lowerLimit": "6.06", "upperLimit": "86.67"}]}]}, {"title": "Month >54-57", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "72.00", "lowerLimit": "72.00", "upperLimit": "72.00"}]}]}]}, {"type": "SECONDARY", "title": "Seizure-free Rate Over the Evaluation Period", "description": "Participants were considered seizure free for a given Period or time interval if the participant, completes the Period or time interval, reports no seizures during the Period, and has no more than 10% of days in the Period for which seizure data is not available (ie, \"Not Done\" is reported on the Seizure Count CRF). The seizure freedom rate (%) for a specific time Period was calculated using the following formula: Count of seizure free participants during the Period/ Number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over the Evaluation Period (up to 5 years)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Quality of Life in Epilepsy 31-P (QOLIE-31-P) Total Score From Visit 3 (Week 2) of EP0069 Through the Assessment of the Evaluation Period of EP0073", "description": "The QOLIE-31-P includes 30 items grouped into 7 multi-item subscales (seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive functioning, medication effects, and social function) and a health status item. Individual responses for the 30 subscale items are rescaled to 0 to 100 with higher scores reflecting better functioning. Each subscale score is then calculated by summing rescaled responses for that subscale and dividing by number of items with non-missing response. Responses for health status item are multiple of 10 ranging from 0 to 100 with a higher score corresponding to better health status. The QOLIE-31-P total score was calculated as weighted sum of the subscale scores which ranges from 0 to 100 with higher score reflecting better functioning.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment and number analyzed signifies participants who were evaluable at specified time points.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Month 3, 7, 13, 19, 25, 31, 37, 43, 49, early discontinuation visit (EDV) (up to Month 58), Relative to Baseline (of EP0069)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}]}], "classes": [{"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.1", "spread": "14.2"}]}]}, {"title": "Month 7", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8", "spread": "17.0"}]}]}, {"title": "Month 13", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.8", "spread": "17.7"}]}]}, {"title": "Month 19", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.7", "spread": "18.0"}]}]}, {"title": "Month 25", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.7", "spread": "24.8"}]}]}, {"title": "Month 31", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.4", "spread": "21.7"}]}]}, {"title": "Month 37", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.4", "spread": "18.8"}]}]}, {"title": "Month 43", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "19.0"}]}]}, {"title": "Month 49", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.6", "spread": "22.2"}]}]}, {"title": "EDV (up to Month 58)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "19.9"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >3-6) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >3-6)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24.4"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >6-9) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >6-9)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.6"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >9-12) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >9-12)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.6"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >12-15) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >12-15)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "23.1"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >15-18) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >15-18)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "23.1"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >18-21) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >18-21)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.9"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >21-24) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >21-24)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.3"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >24-27) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >24-27)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.1"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >27-30) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >27-30)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >30-33) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >30-33)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.0"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >33-36) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >33-36)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35.0"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >36-39) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >36-39)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.8"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >39-42) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >39-42)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.8"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >42-45) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >42-45)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50.0"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >45-48) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >45-48)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.0"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >48-51) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >48-51)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.0"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >51-54) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >51-54)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.0"}]}]}]}, {"type": "PRIMARY", "title": "75% Responder Rate by 3-month Interval (Month >54-57) Over the Evaluation Period", "description": "A 75% responder is defined as a participant with a \u226575% reduction in partial-onset seizure (POS) frequency for observable focal-onset seizures relative to the 2-week Prospective Outpatient Baseline Period defined in EP0069. Observable focal-onset seizures refer to Type IA1 (simple partial seizures with motor signs), IB (complex partial seizures), and IC (partial seizures evolving to secondarily generalized seizures) of the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981. It was calculated using formula: Count of 75% responders during the Period/ number of participants during the Period \u00d7 100.", "populationDescription": "The FAS consisted of all enrolled study participants who took at least 1 dose of UCB0942 and completed at least 1 seizure diary during the Evaluation Period in EP0073. Here, number of participants analyzed included those participants who were evaluable for the assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Over 3-month interval over the Evaluation Period (Month >54-57)", "groups": [{"id": "OG000", "title": "UCB0942 (FAS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the FAS."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From Entry Visit to End of Safety Follow-Up Visit (up to approximately 5 years)", "description": "Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that started on or after the first dose of UCB0942 in EP0073 or AEs whose intensity worsened on or after the date of first dose of UCB0942 in EP0073.", "eventGroups": [{"id": "EG000", "title": "UCB0942 (SS)", "description": "All enrolled participants continued the same UCB0942 dose which they were receiving during last visit of study EP0069 and the dose could be further increased or decreased in participants to optimize the drug tolerability and seizure control for each participant. Daily UCB0942 film-coated tablets were administered orally in doses of 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid) for up to approximately 5 years. Participants formed the Safety Set (SS).", "deathsNumAffected": 0, "deathsNumAtRisk": 42, "seriousNumAffected": 12, "seriousNumAtRisk": 42, "otherNumAffected": 32, "otherNumAtRisk": 42}], "seriousEvents": [{"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 42}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Animal bite", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Face injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Lip injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Procedural nausea", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Subdural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Status epilepticus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 42}]}, {"term": "Dementia Alzheimer's type", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Generalised tonic-clonic seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Memory impairment", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Seizure cluster", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Myomectomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Therapy change", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}], "otherEvents": [{"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 9, "numAtRisk": 42}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 6, "numAtRisk": 42}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 42}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 42}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 42}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 11, "numAtRisk": 42}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 42}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 42}]}, {"term": "Memory impairment", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 42}]}, {"term": "Depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Irritability", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA v22.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 42}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."}, "pointOfContact": {"title": "UCB", "organization": "Cares", "email": "UCBCares@ucb.com", "phone": "001-844-599-2273"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-11-09", "uploadDate": "2021-11-22T06:14", "filename": "Prot_000.pdf", "size": 1230842}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-10-09", "uploadDate": "2021-11-22T06:14", "filename": "SAP_001.pdf", "size": 1813916}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}, {"id": "D000004828", "term": "Epilepsies, Partial"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M15452", "name": "Seizures", "relevance": "LOW"}, {"id": "M7984", "name": "Epilepsies, Partial", "asFound": "Focal Epilepsy", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": true}